Current Treatment Landscape for CLL
Javier Pinilla-Ibarz, MD, PhD, senior member of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the current treatment landscape of chronic lymphocytic leukemia.
Javier Pinilla-Ibarz, MD, PhD, senior member of the Department of Malignant Hematology at Moffitt Cancer Center, discusses the current treatment landscape of chronic lymphocytic leukemia (CLL).
Over the last 5 to 10 years, Pinilla-Ibarz says the landscape has changed dramatically. In the past, there were only monoclonal antibodies and chemotherapy, but now a number of new treatments have been introduced to this patient population, including B-cell receptor inhibitors.
The use of ibrutinib (Imbruvica), a BTK inhibitor, is increasing in the first- and second-line. Pinilla-Ibarz says this is where the change of paradigm began for the treatment of CLL. There was also the introduction and approval of other B-cell receptor inhibitors like idealisib. Acalabrutinib (Calquence), which is approved for the treatment of mantle cell lymphoma, is also showing promise in CLL, as well as PI3K delta inhibitors like umbralisib and duvelisib.
Targeted Therapies Continue to Push the Field of EGFRm Lung Cancer Forward
December 6th 2023In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.
Read More
